S1. Clinical characteristics according to percent change of gMDSC count.

Variables	gMDSC increase <44% (n=45)	gMDSC increase ≥44% (n=21)	P
gMDSC, granulocytic myeloid-derived suppressor cell; ECOG PS, Eastern Cooperative Oncology Group performance status; TTP, time-to-progression; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase.
Age (year) ( )	54.5±10.9	54.2±11.9	0.943
Male gender [n (%)]	30 (66.7)	11 (52.3)	0.535
ECOG PS [n (%)]			0.763
0−1	43 (95.6)	19 (90.5)
2	2 (4.4)	2 (9.5)
TTP with first-line therapy (month) [median (IQR)]	6.6 (4.7−10.9)	5.7 (3.2−12.8)	0.334
NLR [median (IQR)]	1.8 (1.3−2.7)	1.9 (1.2−2.5)	0.983
Hemoglobin (g/dL) ( )	11.7±1.4	11.4±1.9	0.426
LDH (IU/L) [median (IQR)]	212.0 (182.5−251.5)	194.0 (187.0−240.0)	0.776